Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
Incyte Corporation
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Janssen Research & Development, LLC
Hackensack Meridian Health
Novartis
Memorial Sloan Kettering Cancer Center
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
AstraZeneca
National Cancer Institute (NCI)